atrial fibrillation

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathMajor bleeding

antiarrythmic drugs

not classified
SMART, 2002     aprindineplaceboLow risk of bias negative
AFIB, 1997     bidisomideplacebonegative101%
P-OM3 (Kowey), 2010   n-3 PUFAplaceboLow risk of bias negative
Okishige, 2000     pilsicainideplacebosuggesting+Infini%
RACE II, 2010    NCTlenient rate controlstrict rate controlRisk of bias negative46%
amiodarone
Channer, 2004     amiodaroneplaceboLow risk of bias suggesting
GEFACA, 2001   amiodaroneplaceboLow risk of bias suggesting
Kochiadakis (amiodarone vs placebo), 2000       amiodaroneplacebosuggesting
SAFE-T (amiodarone vs placebo), 2005       amiodaroneplaceboLow risk of bias suggesting114%
AFFIRM Substudy (amiodarone vs class I drugs), 2003     amiodaroneclass I drugsRisk of bias suggesting-58%
AFFIRM Substudy (sotalol vs class I drugs), 2003     amiodaroneclass I drugs -
Villani, 1992   amiodaronedisopyramidesuggesting
Kochiadakis a, 2004       amiodaronepropafenonenegative
Vitolo, 1981   amiodaronequinidinesuggesting
AFFIRM Substudy (amiodarone vs sotalol), 2003     amiodaronesotalolsuggesting-40%
Kochiadakis (amiodarone vs sotalol), 2000     amiodaronesotalol -
SAFE-T (amiodarone vs sotalol), 2005     amiodaronesotalolLow risk of bias -
Azimilide
ASAP, 2003             AzimilideplaceboLow risk of bias negative 23%
disopyramide
Karlson, 1998     disopyramideplacebonegative+Infini%
Lloyd (Disopyramide vs placebo), 1984   disopyramideplaceboLow risk of bias negative
PRODIS, 1996   disopyramidepropafenoneLow risk of bias negative+Infini%
Lloyd (Disopyramide vs quinidine), 1984   disopyramidequinidineLow risk of bias -
dofetilide
DIAMOND, 2001       dofetilideplaceboLow risk of bias suggesting-1%
SAFIRE-D, 2000     dofetilideplaceboLow risk of bias suggesting-25%
dronedarone
EURIDIS, 2007      NCTdronedaroneplaceboLow risk of bias suggesting
ADONIS, 2007    NCTdronedaroneplaceboLow risk of bias suggesting
DAFNE, 2003     dronedaroneplaceboLow risk of bias suggesting+Infini%
EURIDIS ADONIS (pooled analysis), 2009   dronedaroneplaceboLow risk of bias negative32%
ATHENA, 2009      NCTdronedaroneplaceboLow risk of bias suggesting -16%
PALLAS, 2011        NCTdronedaroneplaceboLow risk of bias negative 128%
ERATO, 2008   dronedaroneplaceboLow risk of bias negative+Infini%
DIONISOS, 2007      NCTdronedaroneamiodaroneLow risk of bias suggesting -59%
flecainide
Van Gelder, 1989   flecainideno treatmentnegative
Carunchio (flecainide vs placebo), 1995   flecainideplacebosuggesting
Steinbeck (flecainide vs digoxin), 1988   flecainidedigoxinsuggesting
Aliot, 1996     flecainidepropafenonesuggesting-100%
Naccarelli, 1996     flecainidequinidineLow risk of bias negative
metoprolol
Kuhlkamp, 2000     metoprololplacebonegative +Infini%
propafenone
Bellandi (propafenone vs placebo), 2001     propafenoneplaceboLow risk of bias suggesting
Dogan, 2004   propafenoneplacebosuggesting-100%
Kochiadakis b (propafenone vs placebo), 2004       propafenoneplacebosuggesting
RAFT, 2003     propafenoneplaceboLow risk of bias suggesting
Stroobandt, 1997     propafenoneplaceboLow risk of bias negative-100%
FAPIS, 1996       propafenoneflecainidenegative
Richiardi, 1992   propafenonequinidinenegative -100%
Reimold, 1993     propafenonesotalolnegative+Infini%
quinidine
Hillestad, 1971     quinidineno treatmentnegative+Infini%
Sodermark, 1975     quinidineno treatmentsuggesting 105%
Lloyd (quinidine vs placebo), 1984   quinidineplaceboLow risk of bias negative+Infini%
PAFAC (quinidine vs placebo), 2004       quinidineplaceboLow risk of bias suggesting5%
SOPAT (quinidine vs placebo), 2004       quinidineplaceboLow risk of bias suggesting+Infini%
Byrne Quinn, 1979     quinidineplaceboLow risk of bias suggesting+Infini%
Steinbeck (quinidine vs digoxin), 1988   quinidinedigoxinnegative
Lloyd (quinidine vs disopyramide), 1984   quinidinedisopyramideLow risk of bias -
Steinbeck (quinidine vs flecainide), 1988   quinidineflecainide -
Hohnloser, 1995     quinidinesotalolnegative
Juul-Moller, 1990   quinidinesotalolnegative 15%
Kalusche, 1994   quinidinesotalolnegative+Infini%
SOCESP, 1999     quinidinesotalolnegative-100%
PAFAC (quinidine vs sotalol), 2004     quinidinesotalolLow risk of bias -
SOPAT (quinidine vs sotalol), 2004   quinidinesotalolLow risk of bias -
sotalol
Benditt, 1999     sotalolplaceboLow risk of bias negative
Singh, 1991   sotalolplaceboLow risk of bias suggesting
Bellandi (sotalol vs placebo), 2001   sotalolplaceboLow risk of bias suggesting
Carunchio (sotalol vs placebo), 1995   sotalolplacebosuggesting
Kochiadakis (sotalol vs placebo), 2000   sotalolplacebo -
Kochiadakis b (sotalol vs placebo), 2004     sotalolplacebosuggesting
PAFAC (sotalol vs placebo), 2004     sotalolplaceboLow risk of bias suggesting49%
SAFE-T (sotalol vs placebo), 2005       sotalolplaceboLow risk of bias suggesting153%
SOPAT (sotalol vs placebo), 2004   sotalolplaceboLow risk of bias negative+Infini%
Plewan, 2001     sotalolbisoprololnegative
Carunchio (sotalol vs flecianide), 1995   sotalolflecainide -
Kochiadakis b (sotalol vs propafenome), 2004   sotalolpropafenone -

antithrombotics

not classified
Japanese AF Trial, 2006     aspirincontrol -
EAFT, 1993   oral anticoagulantplacebosuggesting
ENGAGE-AF TIMI 48 Low dose, 2013    NCTedoxaban low dosewarfarin standard doseLow risk of bias suggesting -13%-53%
phase 2 AZD0837    NCTAZD0837aspirinExploratory -
NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004     triflusal+coumadin medium dosecoumadin standard doseRisk of bias suggesting
NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004     triflusal+coumadin medium dosetriflusalLow risk of bias suggesting
SIFA, 1997      NCTIndobufenwarfarinsuggesting-100%
Lip (phase 2 AZD0837), 2009    NCTAZD0837warfarin standard doseExploratory -
phase 2 YM150    NCTYM150warfarin standard doseExploratory -
apixaban
AVERROES, 2011        NCTapixabanaspirinineligible for VKALow risk of bias suggesting -21%14%
ARISTOTLE, 2011        NCTapixabanwarfarin standard doseLow risk of bias conclusive-11%-30%
phase 2 apixaban    NCTapixabanwarfarin standard doseExploratory -
aspirin
LASAF(aspirin vs no treatment), 1999     aspirincontrol -
AFASAK (aspirin vs placebo), 1989   aspirinplaceboLow risk of bias negative+Infini%
SPAF (aspirin,warfarin ineligible arm), 1991   aspirinplaceboineligible for VKALow risk of bias negative
SPAF (aspirin , warfarin eligible arm), 1991   aspirinplaceboLow risk of bias suggesting
EAFT, 1993   aspirinplaceboLow risk of bias negative
FFAACS , 2001     aspirinplacebo (on top fluidione)Low risk of bias negative
PATAF (vs coumadin low dose), 1999     aspirincoumadin low doseRisk of bias negative
PATAF (vs coumadin standard dose), 1999     aspirincoumadin standard doseRisk of bias negative
AFASAK II (aspirin vs warfarin low dose), 1998     aspirinwarfarin low doseRisk of bias negative131%65%
SPAF II (aspirin vs warfarin standard dose, age<75), 1994   aspirinwarfarin standard doseRisk of bias negative
AFASAK II (aspirin vs warfarin standard dose), 1998     aspirinwarfarin standard doseRisk of bias negative
SPAF II (aspirin vs warfarin standard dose, age>75), 1994   aspirinwarfarin standard doseRisk of bias negative
AFASAK (aspirin vs warfarin standard dose), 1989   aspirinwarfarin standard doseRisk of bias negative
clopidogrel
ACTIVE W, 2006    NCTaspirin + clopidogrelanticoagulantRisk of bias suggesting 2%10%
ACTIVE A, 2009      NCTaspirin + clopidogrelaspirinLow risk of bias suggesting -2%57%
coumadin
PATAF (coumadin low dose vs coumadin standard dose), 1999     coumadin low dosecoumadin standard doseRisk of bias negative
dabigatran
RE-LY 110mg (2nd prevention subgroup) , 2010   dabigatran 100mgwarfarinExploratory suggesting
RE-LY 150mg (2nd prevention subgroup)   dabigatran 150mgwarfarinExploratory suggesting
phase 2 dabigatran    NCTdabigatranwarfarin standard doseExploratory -
RE-LY (110mg), 2009      NCTdabigatran 110mgwarfarin standard doseRisk of bias suggesting-9%-20%
PETRO (150mg), 2007     dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009      NCTdabigatran 150mgwarfarin standard doseRisk of bias suggesting -12%-7%
edoxaban
Weitz (edoxaban phase 2)    NCTedoxabanwarfarin standard doseExploratory -
phase 2 edoxaban    NCTedoxabanwarfarin standard doseExploratory -
ENGAGE-AF TIMI 48 High dose, 2013    NCTedoxaban high dosewarfarin standard doseLow risk of bias suggesting -8%-20%
idraparinux
AMADEUS, 2008      NCTidraparinuxwarfarin standard doseRisk of bias negative 12%167%
rivaroxaban
ROCKET (2nd prevention subgroup) , 2011   rivaroxabanwarfarinLow risk of bias